share_log

8-K: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

8-K: GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

8-K:GeoVax公佈2024年第二季度財務業績並提供業務最新情況
美股SEC公告 ·  2024/08/07 20:10

牛牛AI助理已提取核心訊息

GeoVax Labs has secured a major BARDA Project NextGen contract worth over $350 million to advance its dual-antigen COVID-19 vaccine candidate, GEO-CM04S1, into a 10,000-participant Phase 2b clinical trial. The company will receive direct funding of approximately $24.3 million, potentially increasing to $45 million, for manufacturing and trial support. The study will compare GEO-CM04S1 with an FDA-approved mRNA COVID-19 vaccine.The company reported Q2 2024 financial results with a net loss of $5.1 million ($1.99 per share), compared to $5.9 million in Q2 2023. R&D expenses were $4.3 million, while G&A expenses decreased to $1.1 million. Cash balance stood at $1.6 million as of June 30, 2024.In other developments, GeoVax plans to advance Gedeptin into an expanded Phase 2 clinical trial for first-recurrence head and neck cancer patients in H1 2025. The company also achieved a milestone in vaccine manufacturing by producing its first lot of GEO-CM04S1 using a commercial manufacturing platform at Oxford Biomedica.
GeoVax Labs has secured a major BARDA Project NextGen contract worth over $350 million to advance its dual-antigen COVID-19 vaccine candidate, GEO-CM04S1, into a 10,000-participant Phase 2b clinical trial. The company will receive direct funding of approximately $24.3 million, potentially increasing to $45 million, for manufacturing and trial support. The study will compare GEO-CM04S1 with an FDA-approved mRNA COVID-19 vaccine.The company reported Q2 2024 financial results with a net loss of $5.1 million ($1.99 per share), compared to $5.9 million in Q2 2023. R&D expenses were $4.3 million, while G&A expenses decreased to $1.1 million. Cash balance stood at $1.6 million as of June 30, 2024.In other developments, GeoVax plans to advance Gedeptin into an expanded Phase 2 clinical trial for first-recurrence head and neck cancer patients in H1 2025. The company also achieved a milestone in vaccine manufacturing by producing its first lot of GEO-CM04S1 using a commercial manufacturing platform at Oxford Biomedica.
GeoVax Labs已獲得一份價值超過$35000萬的BARDA Project NextGen合同,以推動其雙抗原COVID-19生物-疫苗候選者GEO-CM04S1進入一項10,000名參與者的Phase 20億臨牀試驗。公司將獲得約$2430萬的直接資金,可能增加到$4500萬,用於製造和試驗支持。該研究將比較GEO-CM04S1與FDA批准的mRNA COVID-19生物-疫苗。公司報告2024年第二季度財務結果淨虧損爲$510萬(每股$1.99),相比2023年第二季度的$590萬。研發費用爲$430萬,而一般管理費用減少至$110萬。截至2024年6月30日,現金餘額爲$160萬...展開全部
GeoVax Labs已獲得一份價值超過$35000萬的BARDA Project NextGen合同,以推動其雙抗原COVID-19生物-疫苗候選者GEO-CM04S1進入一項10,000名參與者的Phase 20億臨牀試驗。公司將獲得約$2430萬的直接資金,可能增加到$4500萬,用於製造和試驗支持。該研究將比較GEO-CM04S1與FDA批准的mRNA COVID-19生物-疫苗。公司報告2024年第二季度財務結果淨虧損爲$510萬(每股$1.99),相比2023年第二季度的$590萬。研發費用爲$430萬,而一般管理費用減少至$110萬。截至2024年6月30日,現金餘額爲$160萬。在其他發展中,GeoVax計劃在2025年上半年推動Gedeptin進入擴展的Phase 2臨牀試驗,針對首次復發的頭頸癌患者。公司還通過使用Oxford Biomedica的商業製造平台生產其第一批GEO-CM04S1,實現了生物-疫苗製造的一個里程碑。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。